Insight Molecular Diagnostics (IMDX) Return on Assets (2016 - 2026)

Insight Molecular Diagnostics (IMDX) has 11 years of Return on Assets data on file, last reported at 0.0% in Q1 2026.

• Quarterly Return on Assets changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Assets rose to 0.0% in Q1 2026 per IMDX's latest filing, from 0.0% in the prior quarter.
• The five-year high for Return on Assets was 0.0% in Q4 2023, with the low at 0.01% in Q1 2023.
• Average Return on Assets over 5 years is 0.0%, with a median of 0.0% recorded in 2025.
• The widest YoY moves for Return on Assets: up 0 bps in 2022, down 0 bps in 2022.
• Insight Molecular Diagnostics' Return on Assets stood at 0.0% in 2022, then jumped by 91 bps to 0.0% in 2023, then sank by 540 bps to 0.0% in 2024, then decreased by 26 bps to 0.0% in 2025, then advanced by 19 bps to 0.0% in 2026.
• Business Quant data shows IMDX's Return on Assets at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.